Reaction: Mirvetuximab soravtansine to 1 product

Reaction
Mirvetuximab soravtansine
DB12489
    DM4
    DBMET03570
    Reaction type
    cleavage
    Direction
    Major circulating metabolite?
    No
    Spontaneous?
    No
    Activity
    active
    References
    1. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ: A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan;14(2):123-136. doi: 10.2217/fon-2017-0379. Epub 2017 Nov 3. [Article]
    2. Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM: IMGN853, a Folate Receptor-alpha (FRalpha)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRalpha-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22. [Article]
    3. FDA Approved Drug Products: ELAHERE (mirvetuximab soravtansine-gynx) injection for intravenous use [Link]
    Comments
    Not Available
    Enzymes
    Not Available